Therapies
Investors take note of Opthea’s potential
Australian biotech company Opthea has reported a solid cash position to further advance clinical trials of its lead drug candidate...
Read moreNew Australian study results add to Ozurdex?s efficacy
A significant Australian study into the effectiveness of Allergan’s Ozurdex implant as a treatment for Diabetic Macular Oedema (DME) has...
Read more
Shares soar as Australian AMD drug outperforms Lucentis
Melbourne-based biotech company Opthea has demonstrated that combination therapy involving its lead drug candidate OPT-302 is superior to standalone Lucentis...
Read more
Menicon launches new daily disposable CL
O=MEGA PREVIEW: Menicon Australia will be introducing the newest addition to the Miru family of contact lenses.The company will launch...
Read more
New dry eye treatments unveiled at Good Optical Services stand
O=MEGA PREVIEW: Good Optical Services will display NuLids, a simple at-home dry eye treatment, as well as a new Sterileyes...
Read more
Visioneering Technologies targets $11.1 million in new financing
ASX-listed medical device company Visioneering Technologies (VTI) is aiming to raise up to $11.1 million in new capital after securing...
Read more
Research suggests tears could be used to detect glaucoma
A new research project examining the proteins that circulate in the eye’s fluids has the potential to pave the way...
Read more
Researchers engineer self-clearing glaucoma drainage device
US biomedical researchers have developed a self-clearing glaucoma drainage device that uses vibration technology to disperse harmful micro-organisms. The implanted...
Read more